Gujarat Magazine

Alpha-1 Antitrypsin Deficiency Pipeline Assessment, 2024 | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Companies | Octapharma, Dicerna Pharma

 Breaking News
  • No posts were found

Alpha-1 Antitrypsin Deficiency Pipeline Assessment, 2024 | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Companies | Octapharma, Dicerna Pharma

May 22
21:30 2024
Alpha-1 Antitrypsin Deficiency Pipeline Assessment, 2024 | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Companies | Octapharma, Dicerna Pharma
Alpha 1 Antitrypsin Deficiency Pipeline Insight
As per DelveInsight’s assessment, globally, about 12+ key pharma and biotech companies are working on 12+ pipeline drugs in the Alpha-1 Antitrypsin Deficiency (AATD) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Alpha-1 Antitrypsin Deficiency (AATD) Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Alpha-1 Antitrypsin Deficiency Market. 

The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.  The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Alpha-1 Antitrypsin Deficiency (AATD) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Alpha-1 Antitrypsin Deficiency and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Alpha-1 Antitrypsin Deficiency market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Alpha1-Antitrypsin Deficiency (AATD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Types

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Mechanism of Action of the Emerging Pipeline Therapies

  • Immunomodulators; Serine endopeptidase inhibitors

  • Alpha 1 antitrypsin modulators

  • Alpha 1 antitrypsin inhibitors; RNA interference

  • Leucocyte elastase inhibitors

  • Alpha 1 antitrypsin modulators; RNA interference

Learn How the Ongoing Clinical & Commercial Activities will Affect the Alpha-1 Antitrypsin Deficiency Therapeutic Segment @ https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight

Alpha-1 Antitrypsin Deficiency Therapeutics Landscape

There are approx. 12+ key companies developing therapies for Alpha1-Antitrypsin Deficiency (AATD). Currently, Arrowhead Pharmaceuticals is leading the therapeutics market with its Alpha1-Antitrypsin Deficiency (AATD) drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Alpha-1 Antitrypsin Deficiency Therapeutics Market Include:

  • Alnylam Pharmaceuticals

  • Arrowhead Pharmaceuticals

  • Beam Therapeutics

  • Centessa Pharmaceuticals

  • CSL Behring

  • Grifols

  • Inhibrx

  • Kamada

  • Kamada Ltd

  • LFB Biotechnologies

  • Mereo Biopharma

  • Promethera Biosciences

  • Santhera Pharmaceuticals

  • Shire

  • WaVe Life Sciences

And Many Others

Alpha1-Antitrypsin Deficiency (AATD) Drugs Covered in the Report Include

  • ALN-AAT02: Alnylam Pharmaceuticals

  • Alvelestat: Mereo Biopharma)

  • ARO AAT: Arrowhead Pharmaceuticals

  • DCR-A1AT: Dicerna Pharmaceuticals, Inc.

  • INBRX-101: Inhibrx, Inc.

  • Kamada-AAT for Inhalation: Kamada, Ltd.

  • VX-864: Vertex Pharmaceuticals Incorporated

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight

Table of Contents

1. Report Introduction

2. Executive Summary

3. Alpha-1 Antitrypsin Deficiency Current Treatment Patterns

4. Alpha-1 Antitrypsin Deficiency – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Alpha-1 Antitrypsin Deficiency Late Stage Products (Phase-III)

7. Alpha-1 Antitrypsin Deficiency Mid-Stage Products (Phase-II)

8. Alpha-1 Antitrypsin Deficiency Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Alpha-1 Antitrypsin Deficiency Discontinued Products

13. Alpha-1 Antitrypsin Deficiency Product Profiles

14. Key Companies in the Alpha-1 Antitrypsin Deficiency Market

15. Key Products in the Alpha-1 Antitrypsin Deficiency Therapeutics Segment

16. Dormant and Discontinued Products

17. Alpha-1 Antitrypsin Deficiency Unmet Needs

18. Alpha-1 Antitrypsin Deficiency Future Perspectives

19. Alpha-1 Antitrypsin Deficiency Analyst Review  

20. Appendix

21. Report Methodology

Download Sample PDF to Explore the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Recent Posts

Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs, and Companies

Read Full Article

Categories